Karyopharm Therapeutics

Karyopharm Therapeutics is a Newton, Massachusetts-based commercial-stage pharmaceutical company developing and commercializing novel therapies for cancer and other diseases, with its lead asset XPOVIO (selinexor), an oral selective inhibitor of nuclear export (SINE) compound approved by the FDA for multiple oncology indications including multiple myeloma, endometrial cancer, and diffuse large B-cell lymphoma. The company is also advancing selinexor in myelofibrosis through its XPORT-MF-034 Phase 3 trial and exploring next-generation SINE compounds. In May 2026 stockholders approved an amendment to the 2022 Equity Incentive Plan (3.0M new shares added; Form 8-K May 21, 2026), and on July 13, 2026 the Board implemented a 2026 Leadership Cash & Equity Retention Program covering all named executive officers and the CFO using performance-based restricted stock units with a market-cap vesting hurdle (Form 8-K July 17, 2026, accession 0001193125-26-307964).